Pedram Navid1, Linh Nguyen2, Diana Jaber3, Kate Zarzuela1, Mahad Musse1, Marcos Lu Wang4, Tatiana Requijo4, Elissa Kozlov5, Ruth M Masterson Creber6, Sarah N Hilmer7, Mark Lachs1, Parag Goyal1. 1. Department of Medicine, Weill Cornell Medicine, New York, New York, USA. 2. School of Medicine, University of Colorado, Boulder, Colorado, USA. 3. School of Medicine and Health Sciences, George Washington University, Washington, District of Columbia, USA. 4. Department of Medicine, Weill Cornell Medical College, New York, New York, USA. 5. Institute for Health, Health Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, USA. 6. Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA. 7. Kolling Institute, University of Sydney and Royal North Shore Hospital, Sydney, New South Wales, Australia.
Abstract
BACKGROUND/ OBJECTIVES: Attitudes toward deprescribing could vary among subpopulations. We sought to understand patient attitudes toward deprescribing among patients with heart failure with preserved ejection fraction (HFpEF). DESIGN: Retrospective cohort study. SETTING: Academic medical center in New York City. PARTICIPANTS: Consecutive patients with HFpEF seen in July 2018-December 2019 at a program dedicated to providing care to older adults with HFpEF. MEASUREMENTS: We assessed the prevalence of vulnerabilities outlined in the domain management approach for caring for patients with heart failure and examined data on patient attitudes toward having their medicines deprescribed via the revised Patient Attitudes Toward Deprescribing (rPATD). RESULTS: Among 134 patients with HFpEF, median age was 75 (interquartile range 69-82), 60.4% were women, and 35.8% were nonwhite. Almost all patients had polypharmacy (94.0%) and 56.0% had hyperpolypharmacy; multimorbidity (80.6%) and frailty (78.7%) were also common. Overall, 90.3% reported that they would be willing to have one or more of their medicines deprescribed if told it was possible by their doctors; and 26.9% reported that they would like to try stopping one of their medicines to see how they feel without it. Notably, 91.8% of patients reported that they would like to be involved in decisions about their medicines. In bivariate logistic regression, nonwhite participants were less likely to want to try stopping one of their medicines to see how they feel without it (odds ratio 0.25, 95% confidence interval [0.09-0.62], p = 0.005). CONCLUSIONS: Patients with HFpEF contend with many vulnerabilities that could prompt consideration for deprescribing. Most patients with HFpEF were amenable to deprescribing. Race may be an important factor that impacts patient attitudes toward deprescribing.
BACKGROUND/ OBJECTIVES: Attitudes toward deprescribing could vary among subpopulations. We sought to understand patient attitudes toward deprescribing among patients with heart failure with preserved ejection fraction (HFpEF). DESIGN: Retrospective cohort study. SETTING: Academic medical center in New York City. PARTICIPANTS: Consecutive patients with HFpEF seen in July 2018-December 2019 at a program dedicated to providing care to older adults with HFpEF. MEASUREMENTS: We assessed the prevalence of vulnerabilities outlined in the domain management approach for caring for patients with heart failure and examined data on patient attitudes toward having their medicines deprescribed via the revised Patient Attitudes Toward Deprescribing (rPATD). RESULTS: Among 134 patients with HFpEF, median age was 75 (interquartile range 69-82), 60.4% were women, and 35.8% were nonwhite. Almost all patients had polypharmacy (94.0%) and 56.0% had hyperpolypharmacy; multimorbidity (80.6%) and frailty (78.7%) were also common. Overall, 90.3% reported that they would be willing to have one or more of their medicines deprescribed if told it was possible by their doctors; and 26.9% reported that they would like to try stopping one of their medicines to see how they feel without it. Notably, 91.8% of patients reported that they would like to be involved in decisions about their medicines. In bivariate logistic regression, nonwhite participants were less likely to want to try stopping one of their medicines to see how they feel without it (odds ratio 0.25, 95% confidence interval [0.09-0.62], p = 0.005). CONCLUSIONS: Patients with HFpEF contend with many vulnerabilities that could prompt consideration for deprescribing. Most patients with HFpEF were amenable to deprescribing. Race may be an important factor that impacts patient attitudes toward deprescribing.
Authors: Emily Reeve; Michael D Wiese; Ivanka Hendrix; Michael S Roberts; Sepehr Shakib Journal: J Am Geriatr Soc Date: 2013-08-26 Impact factor: 5.562
Authors: Emily Reeve; Jennifer L Wolff; Maureen Skehan; Elizabeth A Bayliss; Sarah N Hilmer; Cynthia M Boyd Journal: JAMA Intern Med Date: 2018-12-01 Impact factor: 21.873
Authors: Ian A Scott; Sarah N Hilmer; Emily Reeve; Kathleen Potter; David Le Couteur; Deborah Rigby; Danijela Gnjidic; Christopher B Del Mar; Elizabeth E Roughead; Amy Page; Jesse Jansen; Jennifer H Martin Journal: JAMA Intern Med Date: 2015-05 Impact factor: 21.873
Authors: Eiran Z Gorodeski; Parag Goyal; Scott L Hummel; Ashok Krishnaswami; Sarah J Goodlin; Linda L Hart; Daniel E Forman; Nanette K Wenger; James N Kirkpatrick; Karen P Alexander Journal: J Am Coll Cardiol Date: 2018-05-01 Impact factor: 24.094
Authors: Lina M Brinker; Matthew C Konerman; Pedram Navid; Michael P Dorsch; Jennifer McNamara; Cristen J Willer; Mary E Tinetti; Scott L Hummel; Parag Goyal Journal: Am J Med Date: 2020-08-18 Impact factor: 4.965
Authors: Alexandra B Achterhof; Zsofia Rozsnyai; Emily Reeve; Katharina Tabea Jungo; Carmen Floriani; Rosalinde K E Poortvliet; Nicolas Rodondi; Jacobijn Gussekloo; Sven Streit Journal: PLoS One Date: 2020-10-26 Impact factor: 3.240
Authors: Parag Goyal; Monika M Safford; Sarah N Hilmer; Michael A Steinman; Daniel D Matlock; Mathew S Maurer; Mark S Lachs; Ian M Kronish Journal: Br J Clin Pharmacol Date: 2022-07-13 Impact factor: 3.716